The core technology of the TheraMe! approach is covered by a granted US patent (US20140332083A1). Furthermore, we have filed two more patent applications on additional technology that also protect our future developments (EP14186463.7 and EP15174088.3). Taken together, the TheraMe! consortium has a comprehensive patent portfolio, putting it in a unique position to offer microfluidics-guided personalized medicine approaches.